Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valeria N Azarova"'
Autor:
Andrey A. Ivashchenko, Valeria N. Azarova, Alina N. Egorova, Ruben N. Karapetian, Dmitry V. Kravchenko, Natalia V. Krivonos, Vladimir G. Loginov, Stanislav V. Poyarkov, Elena A. Merkulova, Olga S. Rosinkova, Nikolay P. Savchuk, Mikhail A. Topr, Elena N. Simakina, Elena V. Yakubova, Alexandre V. Ivachtchenko
Publikováno v:
Viruses, Vol 13, Iss 7, p 1253 (2021)
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Externí odkaz:
https://doaj.org/article/bdadf2eb06b245cbb92ee84869032a4d
Autor:
Stanislav V Poyarkov, Natalia V Krivonos, Elena N Simakina, Olga S Rosinkova, Elena A. Merkulova, Nikolay Filippovich Savchuk, Dmitry V. Kravchenko, Alina N. Egorova, Valeria N Azarova, Elena V Yakubova, Ruben N. Karapetian, Alexandre V. Ivachtchenko, Mikhail A Topr, Andrey Alexandrovich Ivashchenko, Vladimir G Loginov
Publikováno v:
Viruses, Vol 13, Iss 1253, p 1253 (2021)
Viruses
Viruses
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bd706e1992a0619e41915c22f52a4a8
https://www.mdpi.com/1999-4915/13/7/1253
https://www.mdpi.com/1999-4915/13/7/1253
Autor:
Elena A Smolyarchuk, Natalia V. Vostokova, Andrew A. Blinow, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Nikolay Filippovich Savchuk, Tagir A. Sitdekov, Elena A. Merkulova, Kirill A. Dmitriev, Elena N Simakina, Elena P. Pavlikova, Valeria N Azarova, Natalia A. Papazova, Andrey Alexandrovich Ivashchenko, Alexandre V. Ivachtchenko, Alina N. Egorova, Nikita V. Lomakin, Dmitry V. Kravchenko, Alexey P. Ilin, Ivan G. Gordeev
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4109742bd2d16e1c3759cb50b641d0e5
Autor:
Ivan G. Gordeev, Andrey Alexandrovich Ivashchenko, Alexey P. Ilin, Dmitry V. Kravchenko, Nikolay Filippovich Savchuk, Kirill A. Dmitriev, Nikita V. Lomakin, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Elena N Simakina, Elena A. Merkulova, Natalia V. Vostokova, Natalia A. Papazova, Elena A Smolyarchuk, Alexandre V. Ivachtchenko, Andrew A. Blinow, Elena P. Pavlikova, Tagir A. Sitdekov, Alina N. Egorova, Valeria N Azarova
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4c74b1b527e94b4d82f6b1475524f5
Autor:
Sergey Baranovsky, Ludmila Krikunova, Vladimir Kostorov, Natalia Vadimovna Vostokova, Andrew Cakana, Alla Lisyanskaya, Vladimir Ivanovich Vladimirov, Valeria N Azarova, Sergei Tjulandin, Oksana Vladimirovna Karavaeva, Mikhail Fedyanin
Publikováno v:
Journal of Clinical Oncology. 35:5541-5541
5541 Background: Quisinostat is an orally bioavailable potent pan-histone deacetylase inhibitor. Combinations of HDAC inhibitors with paclitaxel or cisplatin demonstrate promising results in preclinical models with cisplatin and paclitaxel resistant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::537a6b6c47d24610682dd6bbf8f5a903
https://doi.org/10.1200/jco.2017.35.15_suppl.5541
https://doi.org/10.1200/jco.2017.35.15_suppl.5541